

Full Title: “Safety and efficacy of Pulmonary physiotherapy in hospitalized patients with severe COVID-19 pneumonia (PPTCOVID): A prospective, randomised, single-blind, controlled trial”

Short Title: “Safety and efficacy of Pulmonary physiotherapy in patients with severe COVID-19”

Authors:

Mohammad Javaherian, Ph.D. Candidate

Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.

ORCID: 0000-0002-4928-1566

Liver Transplantation Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Prof Azadeh Shadmehr, Ph.D.

Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.

ORCID: 0000-0002-1186-9997

Abbasali Keshtkar, Ph.D.

Department of Health Sciences Education Development, School of Public Health, Tehran University of Medical Sciences and Health Services, Tehran, Iran. ORCID: 0000-0002-7305-8639

Mohammad Taghi Beigmohammadi, MD.

Department of Anesthesiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. ORCID: 0000-0002-1925-8760

Narges Dabbaghipour, M.Sc.

Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.

ORCID: 0000-0002-4235-1322

Aabis Syed, M.Sc. Candidate

Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.

Behrouz Attarbashi Moghaddam, Ph.D.

Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.

ORCID: 0000-0002-0184-8930

Correspondence to: Dr. Behrouz Attarbashi Moghaddam

Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran;

Address: Pich-e-Shemiran, Enghelab Street, Tehran, Iran; Postal Code: 1148956111; Email: Attarbashi@tums.ac.ir;

Telephone: +989121883095

Abstract:

Background: Pulmonary physiotherapy (PPT) is an important therapeutic tool in the management of patients with different types of pulmonary disorders. We aimed to evaluate safety and efficacy of PPT in hospitalized patients with severe COVID-19 pneumonia.

Methods: In this randomised, single-blind, controlled trial, we enrolled hospitalized, non-intubated patients (18 to 75 years with oxygen saturation(Spo₂) in free-air breathing $\leq 90\%$) with COVID-19 pneumonia at a referral hospital. Participants were randomly assigned(1:1) to receive PPT (six sessions PPT with breathing exercises and airway clearance techniques) or basic care. The primary outcomes were venous blood O₂(pO₂) and CO₂(pCO₂) pressures, Spo₂, and three-minute walking test(3MWT) that were assessed before and end of sixth session. Secondary outcomes included level of dyspnea, venous blood PH, one-month mortality, three-month mortality and short form-36 (SF-36) after one and three months. The assessor was blinded to the assignment. This trial is registered with ClinicalTrials.gov(NCT04357340).

Findings: In April 2020, 40 participants were randomly assigned to PPT or basic care groups. At the end of intervention, pO₂mortality rates wererence to baseline measure(AMD) 6.43mmHg [95%CI 2.8,10.07],P<0.0001), pCO₂(AMD -2.1mmHg [95%CI-6.36,2.21],P=0.0011), Spo₂(AMD 4.43% [95%CI 2.04,6.83],P=0.0011), and 3MTW (AMD 91.44m [95%CI 68.88,113.99],P<0.0001) were different between groups. While the mortality rate was not different at one month, at three months it was 25% lower in the PPT group (P=.05). This result needs to be reviewed overall though within the manuscript as it is also reported as insignificant "after considering baseline Spo₂ as a covariate: OR=.16 [.26,1.05], P=.07;table 4). There were no significant difference in all SF-36 domains scores between groups after one and three months except body pain domain which was higher in PPT group than basic group significantly(P=.01). No serious adverse event was observed during PPT sessions.

Conclusion: Early PPT can be considered as a safe and effective therapeutic choice for patients with severe COVID-19.

Keywords: Physiotherapy, Pulmonary, Coronavirus Disease 2019, COVID-19, Rehabilitation

Introduction:

In late December 2019, the coronavirus infection pneumonia epidemic broke out and rapidly spread worldwide [1]. Now almost all countries are challenging with coronavirus disease 2019 (COVID-19). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) not only induced more than two million mortality numbers yet, but it also caused a challenge in healthcare systems and the economic conditions of most countries [2].

Patients with COVID-19 can present influenza-like signs and symptoms like fever (89%), cough (68%), fatigue (38%), excessive pulmonary secretion (EPS) or sputum (34%), and breathlessness (19%). The disease can appear asymptomatic or mild lower respiratory tract illness through severe viral pneumonia with acute respiratory distress syndrome (ARDS) and even death [3].

Pulmonary physiotherapy (PPT) is a comprehensive therapeutic method which is aimed to improve patient's respiratory symptoms, train effective cough, clear the airways, increase symptoms of dyspnea, reduce the complications related to disease, minimize disability and finally improve the health-related quality of life (HRQOL) [4].

Up to now, some studies with different designs and levels of evidence have been suggested PPT strategies for hospitalized patients with various stages of COVID-19 pneumonia [1, 4-11].

Almost all of their recommendations are based on expert opinion origin and reported data from other viral pneumonia diseases such as influenza. These recommendations seem to have not sufficient experimental evidence in connection with COVID-19. Researchers of the original studies have focused on rehabilitative or physical therapy processes after the severe stage of COVID-19 more than the acute stage to recovery muscle wasting, aerobic deconditioning, and possibly happened disability due to prolonged immobility [12].

Early PPT can be tailored in the condition of acute respiratory disease to prevent further muscular and aerobic systems deterioration, helping the therapeutic process, decrease hospitalization duration, and facilitate future recovery [4, 5, 9, 10]. As there are gaps of knowledge about PPT in the severe acute stage of COVID-19, this study was aimed to evaluate the safety and efficacy of PPT on pulmonary functions, aerobic capacity, one-month and three-month HRQOL and mortality rate in non-intubated patients with severe COVID-19 pneumonia.

Method:

Study design

This was a single-center, single-blind, prospective, two parallel-armed randomised controlled trial (RCT) comparing the efficacy of six sessions PPT + basic care with basic care alone in hospitalized patients with COVID-19 pneumonia. This study was conducted at COVID-19 intermediate care wards and intensive care units of Imam Khomeini Hospital Complex (IKHC), Tehran, Iran. IKHC is known as the largest and one of the referral hospitals in Iran. Any related adverse events during three days were monitored and recorded by a data safety monitoring committee. Members of this committee were physicians of intermediate care wards and one medical ethics specialist. They were asked to follow the procedure of applied interventions on patients by researchers and possible occurred adverse events which may be related to PPT. [1] This trial was approved by the Ethical Committee of Tehran University of Medical Sciences (IR.TUMS.VCR.REC.1399.205).

Participants

All participants were patients with COVID-19 pneumonia at severe stage [3]. The inclusion criteria were individuals: 1) 18 to 75 years old; 2) with confirmed COVID-19 by positive reaction real-time polymerase chain reaction test and presence of ground-glass opacification in their chest computed tomography scan (CT-scan); 3) severe stage of COVID-19 pneumonia indicated by peripheral blood oxygen saturation (Spo₂) < 90% after two-minute breathing the free air and respiratory rate > 30 breaths/min ;4) with full consciousness and oriented; 5) able to walk; 6) with O₂ saturation < 90% after; 7) $100 \leq \text{PaO}_2/\text{FiO}_2 \leq 200$ mmHg, and 8) able to read and write in Persian. The exclusion criteria included 1) presence of any type of musculoskeletal disorder prohibits the patient from participating in the study; 2) history of intubation due to COVID-19 pneumonia; and 3) Any type of obvious clinically mental or cognitive impairment. Potentially eligible participants were screened by review the admitted patient's medical records and a preliminary assessment. A signed informed consent form was obtained from all patients after explaining the study details to them.

Participants who met one of the following conditions were withdrawn/dropped out from the study: 1) Unable to complete at least three sessions; 2) Dissatisfaction to continue to the study for any reason; 3) Intubation or passing away during interventions; and; 5) Occurring unpredictable adverse events during applying interventions.

Randomisation and masking

After consent was obtained, eligible individuals were assigned (1:1) to one of the treatment groups using the blocked-balanced randomisation method (block size: 4): 1) the experimental group (received six sessions PPT in addition to basic care interventions) or 2) the control group (received basic care only). Randomization was done manually using sealed envelopes. One of the researchers assigned each patient to the next available randomised number based on the randomised list number. The assessor and statistical analysis team were masked to treatment allocation. The assessor had not any access to patient's medical record. As PPT consists of some techniques required the patient's cooperation actively; therefore, participants masking was impossible.

Procedures

Medical history and demographic data were collected from participants after enrollment. Patients underwent clinical evaluation at baseline, including VBG analysis, 3MWT, Spo2, and level of dyspnea. In order to VBG analysis, blood samples were taken from the upper extremity peripheral veins after two-minutes of breathing free air by a nurse. Samples were immediately analyzed [13].

The interventions were delivered over three days. The number of days and sessions for applying the intervention was determined after analyzing the mean of staying duration at intermediate care wards, where patients with severe COVID-19 were admitted. Based on the result of primary analysis, 78% of patients had admitted to intermediate care wards stayed for 3-4 days and they were then transferred to other care wards (normal care ward or intensive care unit). The mean of patient's staying duration at these wards. Participants in both experimental and control groups received usual medical and nursing care, one session of breathing education with 40 minutes duration includes effective cough; if they felt EPS, diaphragmatic breathing, and upper chest muscles relaxation. They also received an incentive spirometer (IS) and instructions on how to use it. They also were advised to walk as tolerate, even using portable oxygen cylinder.

Addition to basic care interventions, patients allocated to the PPT group received 6 PPT sessions for three days (twice daily). Two expert pulmonary physiotherapists assessed patients immediately before every session to select the techniques based on their findings. It is reported that about 34% of patients with COVID-19 pneumonia present signs and symptoms of EPS [3]. If the patient presented signs and symptoms of EPS presence like wheezing sound, and sputum production, airway clearance techniques (ACTs) were applied. These techniques included active

cycle of breathing (ACBT), vibration, percussion, and postural drainage. If there was any contraindication for these techniques, only an effective cough technique was used. ACTs were continued until successful secretions clearance based on therapists' assessment [14]. These patients and whom without EPS signs and symptoms then received Inspiratory Hold Technique (IHT) exercises. During these exercises, patients held the breath at the end of inspiration without using a Valsalva maneuver following by a relaxed exhalation. The physiotherapists emphasized diaphragmatic breathing while performing the IHT by setting their palmar surface of hand on patients' costal margin bilaterally to facilitate abdominal wall motion. Also, patients were educated to relax their upper chest muscles during exercises [14]. This technique was performed ten times in three sets with 2 minutes rest between each set: 1) Set 1: three-second hold, six-second rest; 2) Set 2: six-second hold; 12-second rest; 3) Set 3: 10-second hold, 20-second rest. A summary of applied PPT techniques, contraindications, and criteria of holding the interventions, is presented in figure 1.

Also, patients in this group underwent mild aerobic exercise by walking training after the third session. Two criteria indicated the end of walking training: 1) O₂ saturation < 80% or 2) RPE > 11-13 based on the Borg's scale [15]. The maximum walking training time was determined six minutes, and individuals could have rest intervals during this period.

Patients underwent a second assessment time at the end of day three (immediately after the sixth session). Participants were also followed up to one month and three months to evaluate their survival rate (using electronic medical records) and HRQOL using telephone assessment of short form-36 (SF-36) questionnaire.

Outcome measures

The primary outcomes were venous blood O₂ & CO₂ pressures (pO₂ & pCO₂, mmHg) from VBG analysis. Arterial blood gas analysis was not selected to measure the O₂ & CO₂ pressures due to two reasons; first, patients in the intermediate care have not artery line and also blood sampling by syringe is a painful procedure; second, it has been shown that VBG analysis can be considered as an acceptable alternative for arterial blood gas analysis in patients with pulmonary diseases [13]. Other primary outcome measures include Spo₂ after 2 minutes breathing free air using index finger pulse oximeter [16], and 3MWT distance [17]. In the 3MWT, patients were

asked to continue walking as their tolerance without portable oxygen receive. Heart rate and Spo2 were monitored and the test was stopped if Spo2 was less than 80%.

The secondary outcomes included the level of dyspnea using the visual analog scale [18] and RPE after 3MWT using Borg's scale [15], PH of VBG, one-month rehospitalization and related mortality rates and, HRQOL by the Persian version of SF-36 after one month and three months [19]. As recruited patients had severe disease, we did not assess their HRQOL at the baseline. We assumed their HRQOL to be similar at baseline in the condition of similarity of other clinical and demographic characteristics.

Statistical analysis:

The sample size of this study was calculated based on published data from study by Altschul and colleagues. Also, minimal clinically important difference for Spo2 was considered 4% based on the recommended value by Tobin and colleagues [20, 21]. Minimal clinically important difference (MCID) and standard deviation (SD) were considered 4% and 8.8%, respectively. After assuming a type I error of .01 and 80% power, a sample size of 13 patients per group was calculated to detect a mean difference (MD) of around 4% Spo2 between PPT and basic care groups. As patients with severe COVID-19 pneumonia may encounter mortality, we estimated a 50% loss during intervention time and one-month follow-up. Finally, 40 patients were considered as a suitable sample size.

Stata version 13. (Stata, College, Statin, Texas) was used to analyze the data. We reported Means \pm SD and frequency counts (%) for continuous and categorical data, respectively. Data normality was checked for all continuous variables using the P-P plot, Q-Q plot, and Shapiro-Wilk test. In the condition of significantly of these tests, "ladder" and "gladder" commands were applied. We used analysis of variance and covariance (ANOVA/ANCOVA) to determine the differences of all continuous data, with the baseline score included as a covariate (one factor, one covariate) [22, 23]. Also, we selected blood Spo2 as another covariate for two reasons; first, Spo2 could be considered one of the important factors to predict mortality in hospitalized patients with COVID-19 pneumonia, as reported by Altschul and colleagues [21]. Second, the MD of blood Spo2 $> .2 \times$ SD of all participants' blood Spo2 [24]. Therefore, another ANCOVA model was analyzed considering each baseline score variable and baseline of Spo2 as covariates (one factor, two covariates). The point estimates of effects were reported as MD with a 95% confidence interval (CI), standardized mean difference (SMD) with 95% CI analyzed by Cohen's d. We considered

.2 - .49, .5 - .79, .8 - 1.19 and, > 1.2 valuables as small, moderate, large, and very large SMD effects. To compare three analysis models and the effectiveness of cofounder/covariable impact on the results, partial eta² effect size was provided. In order to evaluate the importance of each variable baseline values and baseline Spo₂, partial eta² was analysed for each analyzes models (unadjusted, adjusted to baseline variable, and adjusted to baseline variable and baseline Spo₂). Change of partial eta² > 10% between models was considered important. In the analysis of categorical data, intention-to-treat (ITT) analysis was utilized.

The number needed to treat (NNT) was calculated using an online calculator for all measures [25]. Alpha ≤ .05 was considered a statistically significant level.

The study was registered at www.clinicaltrials.gov (ClinicalTrials.gov Identifier NCT04357340).

Modifications to the study protocol

Level of dyspnea, rated perceived exertion (RPE) after the three-minute walking test (3MWT), and PH from venous blood gas (VBG) analysis were considered as secondary outcomes, while they were identified as primary outcomes in registration. History of intubation due to COVID-19 pneumonia was considered as another exclusion criteria. Also, the survival rate and HRQOL assessment were evaluated after three months as second follow-up. The permissions for these amendments were obtained from the ethical committee.

This study was funded by the Tehran University of Medical Sciences (Grant number: 99-1-103-47429).

Funding:

This study was funded by the Tehran University of Medical Sciences. The founder of the study had no role in study design, data collection, analysis, interpretation, or writing the manuscript. The corresponding author had full access to all the data in the study and is responsible for publishing the results.

Results:

In April 2020, 255 patients were screened, of whom 40 (age: 55.5 ± 13.7) met the criteria and were randomly allocated to PPT (n=20) or basic care (n=20) groups. From 20 allocated patients to the PPT group, one (5%) was intubated at the end of the second day and died after nine days. The reason for intubation was suddenly hemodynamic instability, which was diagnosed due to pulmonary embolism. Two patients (10%) in the control group were intubated on the third day due to pneumonia progress and died three and eight days later. After one month, four participants

(10%, two in PPT and two in basic care groups) declined to participate in a telephone-based assessment of SF-36. We found all participant's living and rehospitalization status; therefore, no sample attrition occurred. Accordingly, ITT and per-protocol were the same for categorical data analysis. The trial profile is presented in figure 2.

The two groups were clinically and statistically similar at baseline regarding demographic and clinical characteristics (Table 1).

Table 1. Demographics and clinical characteristics of participants.

	PPT group (n=20)	Basic care group (n=20)
Age (y) (Mean ± SD)	54.4 ± 13.1	56.6 ± 14.4
Sex		
Male, n (%)	13 (65)	25 (62.5)
Female, n (%)	7 (35)	15 (37.5)
Height (cm) (Mean ± SD)	172.4 ± 9.3	173.4 ± 7.4
Weight (kg) (Mean ± SD)	82.6 ± 11.8	79.8 ± 19.3
BMI (kg/m ²) (Mean ± SD)	27.9 ± 4.3	26.2 ± 4.4
Comorbidity, n (%)		
Any comorbidity, n (%)	10 (50)	9 (45)
Diabetes mellitus, n (%)	5 (25)	2 (10)
Cardiovascular disease, n (%)	4 (20)	4 (20)
Pulmonary dysfunction (s), n (%)	1 (5)	1 (5)
Renal failure, n (%)	0 (0)	2 (10)
Others, n (%)	2 (10)	1 (5)
Smoker, n (%)	3 (15)	4 (20)
Occupational environmental exposure, n (%) ^a	2 (10)	3 (15)
Routine Ventilation Type ^b		
Nasal, n (%)	2 (10)	3 (15)
Face mask, n (%)	4 (20)	3 (15)
Partial rebreathing mask, n (%)	13 (65)	12 (60)
CPAP, n (%)	1 (5)	2 (10)
Duration of Stay before enrolment (Mean ± SD)	10.1 ± 11.5	9.5 ± 6.8
Baseline O ₂ saturation (%), Mean ± SD)	83.4 ± 4.9	84.4 ± 3.9

PPT: Pulmonary physiotherapy; SD: Standard deviation; BMI: Body mass index; CPAP: Continuous positive airway pressure

^a defines as patient's exposure to some materials like asbestos, arsenic, coal, etc., which can cause pulmonary disease.

^b Defined as prescribed ventilation type for patient by physician which should be used most of the time.

* All of the participant's characteristics are statistically similar between groups based on t-test and chi-square test.

In the crude model analysis, the mean pO₂ (MD: 5.81 [1.51, 10.11], SDM: .9 [.21, 1.57]), Spo₂ (MD: 3.99 [1.5, 6.47], SMD: 1.07 [.37, 1.76]), 3MWT distance (MD: 81.82 [47.93, 115.7], SMD: 1.61 [.86, 2.35]), level of dyspnea (MD: -2.08 [-2.96, -1.19], SMD: -1.57 [-2.31, -.82]), RPE after walking (MD: -4.04 [-5.76, -2.32], SMD: -1.56 [-2.3, -.82]) and, PH (MD: .06, [.01, .12], SMD: .74 [.71, 1.41]) were statistically significant different between groups in all analysis models ($P \leq .03$, Table 2). Also, pCO₂ was insignificantly decreased (MD: -1.68 [-6.8, 3.44], SMD: -.22 [-.43, .86]). In the ANCOVA with adjusting each variable to its baseline measure, the partial eta² were improved > 10%. Considering baseline Spo₂, partial eta² were slightly reduced in all variables except level of dyspnea which was slightly increased (Table 2).

Table 2. Distribution of different outcomes according to two arms in addition to related effect sizes.

Clinical Outcome	PPT group (n=19)		Basic care group (n=18)		F (P value)**	MD [95 % CI]	SMD [95 % CI]	Partial eta ²
	Baseline ^a	After ^a	Baseline ^a	After ^a				
pO ₂ (mmHg)	29.4 ± 5.3	38.7 ± 5.3	30.6 ± 8.2	32.9 ± 7.5	7.5 (< .01) ^a	5.81 [1.51, 10.11]	.9 [.21, 1.57]	.177
					13.1 (< .01) ^b	6.43 [2.8, 10.07]	1.18 [.48, 1.88]	.276
					8.5 (< .01) ^c	6.39 [2.64, 10.14]	1.15 [.45, 1.84]	.267
pCO ₂ (mmHg)	40 ± 7.3	37 ± 7.2	39.3 ± 8	38.6 ± 8.1	.44 (.51) ^a	-1.68 [-6.8, 3.44]	-.22 [-.43, .86]	.012
					8.43 (< .01) ^b	-2.1 [-6.36, 2.21]	-.32 [-.97, .33]	.027
					6.08 (< .01) ^c	-1.7 [-6.01, 2.65]	-.26 [-.91, .39]	.018
SpO ₂ (free air) (%)	83.4 ± 4.9	90.21 ± 3.4	84.4 ± 3.9	86.2 ± 4	10.63 (< .01) ^a	3.99 [1.5, 6.47]	1.07 [.37, 1.76]	.233
					8.37 (< .01) ^b	4.43 [2.04, 6.83]	1.25 [.53, 1.95]	.294
Distance of 3MWT (m)	46 ± 24.3	149.1 ± 63	50 ± 24.4	67.3 ± 33.1	24.03 (< .01) ^a	81.82 [47.93, 115.7]	1.61 [.86, 2.35]	.407
					50.87 (< .01) ^b	91.44 [68.88, 113.99]	2.72 [1.81, 3.62]	.666
					32.93 (< .01) ^c	91.62 [68.38, 114.86]	2.67 [1.76, 3.55]	.661
Level of Dyspnea	5 ± 2	1.54 ± 1.2	5.19 ± 1.4	3.6 ± 1.5	22.89 (< .01) ^a	-2.08 [-2.96, -1.19]	-1.57 [-2.31, -.82]	.395
					36.6 (< .01) ^b	-1.98 [-2.63, -1.33]	-2.04 [-2.83, -1.23]	.531
					23.73 (< .01) ^c	-1.99 [-2.66, -1.32]	-2 [-2.79, -1.2]	.525
RPE after Walking	16.2 ± 1.6	10.8 ± 3	17 ± 1.3	14.8 ± 2	22.6 (< .01) ^a	-4.04 [-5.76, -2.32]	-1.56 [-2.3, -.82]	.393
					16.72 (< .01) ^b	-3.46 [-5.12, -1.8]	-1.42 [-2.14, -.69]	.346
					11.21 (< .01) ^c	-3.32 [-5.03, -1.62]	-1.34 [-2.05, -.62]	.322
PH from VBG	7.42 ± .08	7.5 ± .07	7.44 ± .06	7.43 ± .1	5.11 (.03) ^a	.06 [.01, .12]	.74 [.71, 1.41]	.127
					6.92 (< .01) ^b	.08 [.02, .13]	.96 [.27, 1.63]	.198
					5.27 (< .01) ^c	.07 [.02, .13]	.9 [.22, 1.57]	.181

PPT: Pulmonary physiotherapy; pO₂: Mixed venous O₂ pressure; pCO₂: Mixed venous CO₂ pressure; SpO₂: Oxygen saturation; 3MWT: Three-minute walk test; RPE: Rating of perceived exertion; VBG: Venous blood gas; MD: Mean difference; CI: Confidence interval; SMD: Standardized mean difference (based on Cohen's d test), ANOVA: Analysis of variance, ANCOVA: Analysis of covariance.

^a Expressed as mean ± standard deviation.

** Analyzed using ANOVA/ANCOVA tests.

^a Crude analysis

^b Adjusted to baseline measurement of the variable (as covariance)

^c Adjusted to baseline measurement of the variable and baseline O₂ saturation (free air) (as covariance)

Table 3 presents all of the SF-36 domains and summary scores after one month and three months. All scores were higher in the PPT group than the basic care group, except body pain after one month and role limitation due to physical health, mental health, and mental component summary score after three months. Only the differences of body pain domain score reach to a statistically significant level.

Table3. Distribution of SF-36 domains according to two arms in addition to related effect sizes after one and three months.

SF-36 Domain	Time	Groups		F (P-value)**	MD [95 % CI]	SMD [95 % CI]	Partial eta ²
		PPT ^a (n=16)	Basic care ^a (n=12)				
PF	one-month ^a	41.7 ± 24.9	35.1 ± 23.1	.5 (.49)	6.53 [-12.44, 25.5]	.27 [-.48, 1.02]	.018
	three-month ^b	45.8 ± 18.6	43.3 ± 18.4	.11 (.74)	2.5 [-12.91, 17.91]	.13 [-.66, .92]	.005
RP	one-month	40.6 ± 44.6	18.7 ± 33.9	2.01 (.17)	21.87 [-9.86, 53.61]	.54 [-.23, 1.3]	.072
	three-month	54.7 ± 33.2	62.5 ± 35.8	.32 (.58)	-7.81 [-36.27, 20.65]	-.23 [-1.02, .57]	.013
BP	one-month	62.5 ± 31.4	69.4 ± 30.1	.35 (.56)	-6.94 [-31.13, 17.25]	-.22 [-.97, .53]	.013
	three-month	77.1 ± 20.1	54.4 ± 22.5	6.82 (.01)	22.64 [4.75, 40.52]	1.05 [.2, 1.89]	.221
GH	one-month	67.5 ± 28.8	60 ± 21.2	.58 (.45)	7.5 [-12.81, 27.81]	.29 [-.46, 1.04]	.021
	three-month	68.1 ± 23.2	61.5 ± 31.2	.38 (.54)	6.62 [-15.42, 28.67]	.25 [-.55, 1.04]	.016
VT	one-month	55.9 ± 32.3	55 ± 18.7	.01 (.93)	.93 [-20.57, 22.44]	.03 [-.71, .78]	.000
	three-month	58.1 ± 20.6	57.5 ± 29.8	.00 (.95)	.62 [-20.97, 19.72]	.02 [-.76, .81]	.000
SF	one-month	71.9 ± 30.4	57.3 ± 29.9	1.6 (.22)	14.59 [-9.13, 38.3]	.48 [-.28, 1.24]	.057
	three-month	76.6 ± 20.8	66.2 ± 27	1.2 (.28)	10.31 [-9.12, 29.75]	.44 [-.36, 1.24]	.046
RE	one-month	68.7 ± 41.2	58.3 ± 45.2	.4 (.53)	10.42 [-23.31, 44.14]	.24 [-.51, .99]	.015
	three-month	75 ± 39.44	73.3 ± 43.9	.01 (.92)	1.67 [-32.58, 35.91]	.04 [-.75, .83]	.000
MH	one-month	71.5 ± 26.3	68 ± 21.7	.14 (.71)	3.5 [-15.7, 22.7]	.14 [-.61, .89]	.005
	three-month	64 ± 16.2	67.6 ± 17.3	.29 (.6)	-3.6 [-17.44, 10.24]	-.22 [-1.01, .58]	.012
MCSS	one-month	51.4 ± 14.5	48.5 ± 16.3	.23 (.63)	2.82 [-14.81, 9.17]	.18 [-.57, .93]	.008
	three-month	50 ± 10.4	50.1 ± 15	.00 (.98)	-.13 [-10.41, 10.14]	.01 [-.8, .78]	.000
PCSS	one-month	37.5 ± 10.5	34.3 ± 12.2	.56 (.46)	3.24 [-5.62, 12.1]	.29 [-.47, 1.04]	.021
	three-month	42.2 ± 10.3	38.9 ± 10.3	.6 (.44)	3.21 [-5.33, 11.76]	.31 [-.48, 1.1]	.024

PF: Physical functioning; RP: Role limitations due to physical health; BP: Body pain; GH: General health; VT: Vitality; SF: Social functioning; RE: Role limitation due to emotional problems; MH: Mental health; MCSS: Mental component summary score; PCSS: Physical component summary score; PPT: Pulmonary physiotherapy; SF-36: Short form-36; Mean difference; SMD: Standardized mean difference (based on Cohen's d test); CI: Confidence interval.

^a Expressed as mean ± standard deviation.

^{**} Analyzed using ANOVA tests.

^a 16 and 12 patients participated to assessment of quality of life after one month in PPT and basic care groups, respectively.

^b 16 and 10 patients participated to assessment of quality of life after three months in PPT and basic care groups, respectively.

During one month after end of the intervention, two and six participants in the PPT group and basic care group were died (OR=.26 [.04, 1.49], P=.11, table 4). After considering baseline Spo₂ as a covariate, OR was reduced (OR=.19 [.03, 1.30], p=.09). After three months, all allocated participants to PPT group were survived and one patient in basic care group was died (crude analysis: OR=.21 [.04, 1.16], P=.05; after considering baseline Spo₂ as a covariate: OR=.16 [.26, 1.05], P=.07; table 4).

Table 4. The mortality rate of participants allocated to groups in addition to related effect sizes.

	Allocated group	Mortality +	Mortality -	Odds ratio [95% CI]	Risk difference [95% CI]	Risk ratio [95% CI]
One-month mortality	PPT group	2 (10%)	18 (90%)	.26 [.04, 1.49]	-.2 [-.44, .04]	.33 [.08, 1.46]
	Basic care group	6 (30%)	14 (70%)			
Three-month mortality	PPT group	2 (10%)	18 (90%)	.21 [.04, 1.16]	-.25 [-.5, -.00]	.29 [.07, 1.21]
	Basic care group	7 (35%)	14 (65%)			

PPT: Pulmonary physiotherapy; CI: Confidence interval

No related adverse events were observed during the intervention period. The physiotherapists reported a minimal Spo2 decrease and minimal hemodynamic instability in some patients during PPT that was resolved a few minutes after the session. Also, the data monitoring committee confirmed that the reason for one case mortality in the experimental group during three days seems to not be related to the PPT.

Discussion:

According to our knowledge, this study is the first RCT to evaluate the efficacy of the PPT through comparison with a control group on non-intubated hospitalized patients with severe COVID-19 pneumonia. Our designed interventions seem to be safe without serious adverse effects.

In general, the results show that participants in the PPT group had improved VBG, Spo2, 3MWT, and level of dyspnea values than the basic care group after adjustment of each measurement to the baseline measure. Based on the result of standardized mean differences, PPT decreased pCO2 with a small effect size (NNT≈ 6) and improved pO2 (NNT≈ 2), venous blood PH (NNT= 2), level of dyspnea (NNT≈ 2), and RPE after walking (NNT≈ 2) with a large effect size, but inconclusive. PPT also improved Spo2 (NNT≈ 2) and distance of 3MWT (NNT≈ 2) with a very large effect size, but inconclusive. The NNT analyzes showed that it seems one patient with severe COVID-19 pneumonia can benefit from the PPT regarding most pulmonary functions, aerobic capacity, and dyspnea measures if it is applied to at least two patients.

After one-month follow-up, PPT was associated with higher HRQOL in role limitation due to physical health (NNT≈ 3) with a moderate effect size. Also, patients in PPT group presented higher score in body pain domain of SF-36 instrument than basic care group (NNT≈ 2) after three months with a large effect size. Patients with COVID-19 suffer from significant physical and psychological impairments that impact their HRQOL; Therefore, interventions improving

HRQOL like rehabilitation should be considered in their management [26]. Although some limited domains of DF-36 presented higher value in PPT group than control group at one-month and three-month with very small effect size, but higher values of other domains in PPT group than control group makes an idea in the mind that prolonged duration rehabilitation, especially after discharge, may improve physical and psychological impairments and HRQOL. It has been shown that six weeks of respiratory rehabilitation could improve respiratory function, aerobic capacity, HRQOL, and anxiety of elderly patients with COVID-19, as reported by Liu and colleagues [12].

Allocated participants to the PPT group had a 20% and 25% lower one-month and three-month mortality rate than the basic care group, respectively. The NNT analysis shows that PPT kept alive one out of five patients until one month. However, the results of logistic test of one-month mortality rate is not statistically significant. Based on the NNT analysis, PPT can keep alive one out of four patients until three months.

Adjusting each variable to its baseline measurement increased partial $\eta^2 > 10\%$ than crude analysis, suggesting that even small differences of each measured outcome can change the results. A similar effect was not found about baseline Spo₂.

There are currently some published studies with different levels of evidence, mostly review of investigations about PPT and other cases of viral pneumonia such as influenza, expert opinions, and consensus statements recommended how and when to use PPT for patients with different stages of COVID-19 pneumonia. Some researchers, physiotherapy, and rehabilitation experts have recommended PPT as an effective rehabilitative intervention for patients with all stages of COVID-19 pneumonia [4, 5, 9, 10]. Other researchers believed that only ACT should be applied in the presence of EPS to patients with the severe stage under special conditions; However, they have not suggested utilizing other PPT techniques like diaphragmatic breathing, respiratory muscle training, incentive spirometers, manual mobilization, and exercise training [1, 6-8, 11]. They explained that acute patients often have a shallow and rapid respiratory pattern that has been adapted spontaneously to make the minimal effort; therefore, any change in this strategy may harm the patient. No other reason was given for considering PPT contraindicated in the severe stage of COVID-19 pneumonia [8]. We observed some of these events like Spo₂ decreasing and cough stimulating, but all were resolved just some minutes after the session. In our clinical setting, we also sometimes observed that Spo₂ decreases during breathing through

continuous positive airway pressure, while using this non-invasive ventilator is recommended [27]. Our results showed that PPT seems not to be a contraindication for severe stage COVID-19, but it also may help therapeutic procedure.

About 34% of patients with COVID-19 pneumonia suffer from EPS [2]; therefore, ACT can be an effective treatment for them [14]. On the other hand, the main cell target of SARS-Cov-2 is type II pneumocyte, which is responsible for pulmonary surfactant synthesis [28]. As the pulmonary surfactant increases pulmonary compliance and facilitates the recruitment of collapsed airways [29], SARS-Cov-2 may cause alveolar stiffness. As there are some time-dependent properties of the tissue like creep and stress relaxation, a possible reason for the rationality of breathing exercises in early phase can be their roles in tissue stiffness reduction or prevent pneumonia progression. Based on this hypothesis, early PPT in the acute phase may have therapeutic, preventive, and rehabilitative roles in the management of COVID-19 pneumonia. We did not have any assessment of lung tissue stiffness; therefore, our results support this possible hypothesis indirectly. Future researches with radiologic assessments that show tissue characteristics like CT-scan can test this hypothesis to some extent.

Our used PPT program had three main characteristics. First, choose the type of PPT technique(s) based on the patients' signs and symptoms. We used IHT with emphasis on diaphragmatic breathing and educated them on how to cough and breathe properly, but ACTs were only applied to patients with EPS signs and symptoms. Second, we also defined some criteria for holding the intervention to get better safety. Third, we set a mild aerobic exercise in addition to chest physiotherapy to prevent muscle wasting and aerobic deterioration, which are seen in patients with COVID-19 [3]. We highly recommend that patients take a sufficient dose of oxygen and be under accurate monitoring during exercises.

Our research had some limitations which should be considered in future studies. First, we selected the sample size as MCID of Spo₂ as the primary outcome measurement, but this number seems to have not enough power for other variables. For example, allocated participants in the PPT group had a 20% lower mortality rate than the control group. This RD seems to be influential; however, the results of logistic tests in the mortality rate did not reach a statistically significant level. Second, we only recruited participants from a single center. Now, different centers have particular therapeutic guidelines that can impact the results of PPT. The applied interventions in this study with three-day duration, no need for specific tools and, low risk of

adverse events suggest the feasibility of multi-center investigations on PPT effectiveness and safety on hospitalized patients with COVID-19. Third, we only recruited patients with a severe stage of COVID-19. Based on the mentioned possible mechanism, PPT may be more effective if to be started before disease severity reaches to severe phase even when the symptoms appear; therefore, future researchers are recommended to investigate the efficacy of PPT in patients with mild and moderate stages of COVID-19. Fourth, we only followed the patients up to one month, assessing only outcomes that can be assessed through telephone and electronic medical records. As participants of this study were from different cities, we could not re-assess their respiratory functions, aerobic capacity, and level of dyspnea.

Conclusion:

The results of this RCT suggest early PPT during three days, including airway clearance techniques, in the presence of excessive pulmonary secretion, and inspiratory hold breathing with emphasis to diaphragmatic breathing for hospitalized adult patients with a severe stage of COVID-19 pneumonia. The influence of early PPT on the mortality rate of these patients is currently indeterminate. Further researches are needed to evaluate the efficacy of PPT on COVID-19 patients with different severity stages.

Contribution

MJ, AS, AK, MTB, ND, and BAM made substantial contributions to the conception and designed the study. MJ, ND, and SA contributed to applying the intervention or acquisition of the data. MJ and AK analysed the data. AK was responsible for the statistical analysis. BAM was responsible for data safety monitoring during the study. MJ, ND, and BAM interpreted the data and drafted the manuscript. MJ and BAM verified the data. All authors had access to the data, revised the manuscript, and approved it.

Declaration of interests:

The authors declare no competing interests.

Data sharing

All individual participant data that underline the results reported in this article, after de-identification (text, tables, figures, and appendices), statistical analysis plan and Informed consent form are available from the corresponding author and Mohammad Javaherian (Email: Javaherian_m@razi.tums.ac.ir) for researchers who provide a related approved proposal and

ethical committee approve to achieve aims. Patient-level information will be anonymised and study documents will be redacted to protect the privacy of trial patients. These data will be available with publication date until one year.

Acknowledgment

The researchers sincerely thank all physicians and nurses of intermediate care wards of IKHC. The authors would like to appreciate the methodologist's support and constructive comments (s) research development office, IKHC, Tehran, Iran.

References:

1. Andrade AD, Nepomuceno B, Xavier DS, Lima E, Gonzalez I, Santos JC, et al. Evidence-based Physiotherapy and Functionality in Adult and Pediatric patients with COVID-19. *J Hum Growth Dev.* 2020; 30: 148-155.
2. World Health Organization. COVID-19 weekly epidemiological update, 19 January 2021. <https://www.who.int/publications/m/item/weekly-epidemiological-update---19-january-2021>
3. World Health Organization. COVID-19 clinical management: living guidance, 25 January 2021. World Health Organization; 2021.
4. Wang TJ, Chau B, Lui M, Lam GT, Lin N, Humbert S. Physical medicine and rehabilitation and pulmonary rehabilitation for COVID-19. *Am J Phys Med Rehabil.* 2020; 99: 769-74.
5. Aytür YK, Köseoğlu BF, Taşkiran ÖÖ, Ordu-Gökkaya NK, Delialioğlu SÜ, Tur BS, et al. Pulmonary rehabilitation principles in SARS-COV-2 infection (COVID-19): A guideline for the acute and subacute rehabilitation. *Turk J Phys Med Rehabil.* 2020; 66: 104-120.
6. Vitacca M, Carone M, Clini EM, Paneroni M, Lazzeri M, Lanza A, et al. Joint statement on the role of respiratory rehabilitation in the COVID-19 crisis: The Italian position paper. *Respiration.* 2020 May 19. doi: 10.1159/000508399.
7. Thomas P, Baldwin C, Bissett B, Boden I, Gosselink R, Granger CL, et al. Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations. *J Physiother.* 2020; 66: 73-82.
8. Lazzeri M, Lanza A, Bellini R, Bellofiore A, Cecchetto S, Colombo A, et al. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR). *Monaldi Arch Chest Dis.* 2020 March 25. doi: 10.4081/monaldi.2020.1285.
9. Liebl ME, Gutenbrunner C, Glaesener JJ. Early rehabilitation in COVID-19—best practice recommendations for the early rehabilitation of COVID-19 patients. *PHYS MED REHAB KUROR.* 2020 May 5. doi: 10.1055/a-1162-4919.

10. Zeng B, Chen D, Qiu Z, Zhang M, Wang G, Wang J, et al. Expert consensus on protocol of rehabilitation for COVID-19 patients using framework and approaches of WHO International Family Classifications. *Aging Med.* 2020 July 6; doi: 10.1002/agm2.12120.
11. Yang LL, Yang T. Pulmonary rehabilitation for patients with coronavirus disease 2019 (COVID-19). *Chronic Dis Transl Med.* 2020 May 14. doi: 10.1016/j.cdtm.2020.05.002.
12. Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study. *Complement Ther Clin Pract.* 2020 April 1. doi: 10.1016/j.ctcp.2020.101166.
13. Theodore AC, Manaker S, Finlay G. Venous blood gases and other alternatives to arterial blood gases. 2019; <https://www.uptodate.com/contents/venous-blood-gases-and-other-alternatives-to-arterial-blood-gases> (accessed January 23).
14. Hillegass E. *Essentials of Cardiopulmonary Physical Therapy: fourth edition.* Missouri: Elsevier Health Sciences, 2016.
15. Wilson RC, Jones PW. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnea during exercise. *Clin Sci.* 1989; 76: 277-282.
16. Louw A, Cracco C, Cerf C, Harf A, Duvaldestin P, Lemaire F, et al. Accuracy of pulse oximetry in the intensive care unit. *Intensive Care Med.* 2001; 27: 1606-1613.
17. Bohannon RW, Bubela DJ, Wang YC, Magasi SS, Gershon RC. Six-minute walk test versus three-minute step test for measuring functional endurance (Alternative Measures of Functional Endurance). *J Strength Cond Res.* 2015; 29: 3240-3244
18. Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. *Rehabil Nurs.* 1989; 14: 323-325.
19. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. *Qual Life Res.* 2005; 14: 875-882.
20. Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. *Am J Respir Crit Care Med.* 2020; 202: 356-360.
21. Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayirli P, Mehler M, et al. A novel severity score to predict inpatient mortality in COVID-19 patients. *Sci Rep.* 2020 October 7. doi: 10.1038/s41598-020-73962-9.
22. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. *BMC Med Res Methodol.* 2001; 1: 1-6.
23. Imbens GW, Rubin DB. *Causal inference in statistics, social, and biomedical sciences.* New York: Cambridge University Press; 2015.
24. De Boer MR, Waterlander WE, Kuijper LD, Steenhuis IH, Twisk JW. Testing for baseline differences in randomized controlled trials: an unhealthy research behavior that is hard to eradicate. *Int J Behav Nutr Phys Act.* 2015 Dec 12. doi: 10.1186/s12966-015-0162-z.

25. Furukawa TA, Leucht S. How to obtain NNT from Cohen's d: comparison of two methods. *PLoS one*. 2011 April 27. doi: 10.1371/journal.pone.0019070.
26. Chen KY, Li T, Gong F, Zhang JS, Li XK. Predictors of health-related quality of life and influencing factors for COVID-19 patients, a follow-up at one month. *Front Psychiatry*. 2020 Nov. doi: 10.3389/fpsyt.2020.00668.
27. Ashish A, Unsworth A, Martindale J, Sundar R, Kavuri K, Sedda L, et al. CPAP management of COVID-19 respiratory failure: a first quantitative analysis from an inpatient service evaluation. *BMJ open respiratory research*. 2020 Nov 1. doi: 10.1136/bmjresp-2020-000692.
28. Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. *Hum Pathol*. 2003; 34: 743-748.
29. Desai JP, Moustarah F. Pulmonary compliance. *StatPearls [Internet]*. 2019 Feb 18.




Fig 1. The protocol of applied pulmonary physiotherapy to patients with or without excessive pulmonary secretion.




Fig 2. Trial profile